TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Bleeding-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Scores of the Hamilton Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Scores of the Montgomery Asberg Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum T concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: UA pulsatility index (PI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: DV pulsatility index (PI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: MCA pulsatility index (PI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: NT-proBNP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: wheezing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: urinary salbutamol excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: clinical efficacy and safety of anacetrapib
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Seroprotection rate (SPR: % with anti‐HBs≥10mIU/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of participants with anti‐HBs≥100mIU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean concentration of anti‐HBs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean SF-36 physical component summary score improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: triglyceride half-life
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: units of AB collected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ml of RBC produced
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of reduced exposure to allogeneic blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of contrast agent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: decrease in white thrombus burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergency Department visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Free plasma tryptophan to LNAA ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GAD-related VAS scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: serum ALT concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: daylong insulin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SSPG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BMD at the lumbar spine, hip and total body
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal bleeding/spotting
Endpoint domain: Adverse events/effects
Primary endpoint: PGE(2) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TxB(2) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma ECs levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to offset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for norepinephrine infusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital admission for bleeding-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Mean cost per patient of anticoagulation
Endpoint domain: Resource use
Primary endpoint: MxA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in anxiety subscale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: exercise readiness maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physical activity decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BAd change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Development of renal adverse events (RAs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serious renal events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rates of vitamin A, D, and E deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Microbiologic samples negative for A actinomycetemcomitans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Jugular bulb desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 9-month probability of survival
Endpoint domain: Mortality/survival
Primary endpoint: Preservation of cervical anatomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete resolution of SUI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: DXA spine BMD increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum osteocalcin increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse effects and toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Glucose metabolism in the lentiform nucleus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median time to maximum concentration (t(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge on primary health care contents
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improvement of at least 75% in subjective and objective scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in mean symptom and sign scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive and behavioral avoidance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reassurance seeking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: A-aDO(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Qmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Urological outcomes
Primary endpoint: Mean AUA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Urological outcomes
Primary endpoint: Lifestyle movement (LM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local recurrence-free rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Distant brain recurrence-free rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Leptin reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional HRQL
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Coronary vessel resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Requests for results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of red blood cell units transfused per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: TMD pain frequency and intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impairment levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AS understanding scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: poor renal outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Radiographic progress of joint destruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: nocturnal awakening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients mycologically cured
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Minimum pulse oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of pulse oxygen saturation ≤ 90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean arterial pressure during intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Absence of laryngoscopy resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postpartum myalgia
Endpoint domain: Adverse events/effects
Primary endpoint: Symptom improvement on CDRS-R
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heartburn resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Positive predictive value of DRSP scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value of DRSP scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of residual and recurrent ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Platelet Induced Clot Retraction (PICR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure rate for urethral gonorrhea
Endpoint domain: Mortality/survival
Primary endpoint: Cure rate for cervical gonorrhea
Endpoint domain: Mortality/survival
Primary endpoint: Cure rate for pharyngeal gonorrhea
Endpoint domain: Mortality/survival
Primary endpoint: Pediatric Anxiety Rating Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent-reported scales of internalizing symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety-associated social functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Incidence of Intraventricular Hemorrhage (IH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Discontinuation rates due to any cause
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of cardiovascular-related AEs of special interest
Endpoint domain: Adverse events/effects
Primary endpoint: Gastrointestinal safety profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean displacement value of sulcus width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative-turning rate of HBVDNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average values of ALT and AST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: number of contact errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of castor errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: children's adaptive skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maternal adaptation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Correlation between A‐LACT and V‐LACT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of V‐LACT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of V‐LACT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat oxidation during the 10-km run
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Phenylalanine oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patients' concentration during AAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' alertness during AAT
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: MTB race performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of recurrences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation in CRC screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fat-Free Mass (FFM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean atrial tachyarrhythmia (AT) burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: health-related quality of life (HRQL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction of ≥ 30% in abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase of ≥ 1 CSBM from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from AF off antiarrhythmic drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum ferritin value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ulcerative Colitis Disease Activity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 h ABP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diarrhea TEAE rate
Endpoint domain: Adverse events/effects
Primary endpoint: Discontinuation due to any adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Discontinuation due to diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Serious adverse event rates
Endpoint domain: Adverse events/effects
Primary endpoint: physical work capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morning hyperglycemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bedtime glycemic level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of clinical soy allergy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Allergic reactions outcomes
Primary endpoint: Rate of methamphetamine-positive urine test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net reductions in depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net reductions in insomnia severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GLP-1 increase after oral glucose tolerance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in resting myocardial perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adverse events, serious adverse events, and major adverse cardiac event
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in fruit and vegetable intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: total stress scores reported by parents
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in number of micturitions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in IPSS storage symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute Radiation Therapy Oncology Group Grade 2 rectal toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: acute Radiation Therapy Oncology Group Grade 2 bladder toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiovascular biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: annual rate of aneurysm rupture
Endpoint domain: Mortality/survival
Primary endpoint: Rate of silent new lesions observed in 72-hour DWMRI
Endpoint domain: Adverse events/effects
Primary endpoint: Step Test improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wii Balance Board-derived centre of pressure scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in children's asthma exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Working time for canal filling
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Decreased UBT in H. pylori-positive subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Carboplatin concentrations in axillary lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postoperative levels of serum IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative levels of C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total bilirubin value on postoperative day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-month restenosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: MALE rate
Endpoint domain: Adverse events/effects
Primary endpoint: Gastric fluid volume 30 minutes after drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Flow rate of gastric emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Residual ratio of gastric contents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Free testosterone (FT) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Protection against varicella
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Initiation of HPV vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Credibility of responses
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Early diastolic tissue Doppler velocity (lateral e')
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mitral peak E velocity to lateral e' ratio (lateral E/e')
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients achieving SeBP goal of <140/90 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effective rate of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lowering effect on triglycerides (TG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decreasing whole blood viscosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: restenosis rate (> 50% residual visual stenosis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: absence of clinical events (death, nonfatal myocardial infarction, coronary artery bypass graft surgery, or repeat angioplasty in target vessel)
Endpoint domain: Adverse events/effects
Primary endpoint: Return of menses (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal high-risk situations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High-grade lesions identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Remission Rate (RR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1- and 2-year Survival Rates
Endpoint domain: Mortality/survival
Primary endpoint: Postnatal care compliance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Platelet function profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative surgical margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Combined risk of major bleeding, INR of 4 or greater, venous thromboembolism, or death
Endpoint domain: Adverse events/effects
Primary endpoint: Rise in T and C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Correlation of Dr-l with T and E2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: T/C ratio and E2/C ratio correlations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 5-year biochemical relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence rate of lung and skin fibrosis
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of new relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression to disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RVm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes